AllDocs -> cancers

16. New Drugs in Oncology / New Diagnosis and Modalities in Cancer Therapy PO442 ENZASTAURIN: CORRELATIONS OF CHEMOSENSITIVITY AND GENE EXPRESSION IN HUMAN SOLID TUMORS Eismann, U. 1 ; Oberschmidt, O. 1 ; Ehnert, M. 1 ; Fleeth, J. 1 ; Lüdtke , F.E. 1 ; Struck, S. 1 ; Schulz, L. 1 ; Blatter , J. 2 ; Lahn, M.M. 2 ; Ma, D. 2 ; Hanauske , A.-R. 1 1 Allgemeines Krankenhaus St. Georg, Hamburg; 2 Eli Lilly & Co, Indianapolis, USA Background: Enzastaurin is a potent and selective inhibitor for the beta-isoform of the protein kinase C (PKC-beta). The enzyme is implicated in processes that control tumor cell growth and survival. It is activated by several growth ...

Journal of Cell and Molecular Biology 3: 89-93, 2004. Haliç University, Printed in Turkey. 89 Introduction: Prostate cancer (pCA) is the most commonly diagnosed noncutaneous malignancy in men in USA and also world wide (American Cancer Society, 2002; DeMarzo et al., 1999). Mortality in prostate carcinoma is associated with metastasis and metastasis in prostate carcinoma is usually associated with perineural invasion, for it is the preferred mechanism of prostate cancer metastasis. One of the current theory states this form of metastasis follows the path of least resistance offered by the perineural sheath. Understanding E-cadherin immunohistochemistry for prostate cancer early diagnosis and monitoring of illness Serdar Arisan*, Cem Sönmez, ‹brahim Duman, Turhan Çaflkurlu, Ayhan Dalk›l›ç, Erbil Ergenekon *fiiflli Etfal Research and Training Hospital, 1st Urology ...

Applying Fuzzy CoCo to Breast Cancer Diagnosis Carlos AndrCs Pefia-Reyes Logic Systems Laboratory Swiss Federal Institute of Technology Lausanne CH-1015 Lausanne, Switzerland Carlos.Pena@epfl.ch Abstract- Coevolutionary algorithms have received in- creased attention in the past few years within the domain of evolutionary computation. In this paper, we combine the search power of coevolutionary computation with the expressive power of fuzzy systems, introducing a novel algorithm, Fuzzy COCO: Fuzzy Cooperative Coevolution. We demonstrate the efficacy of Fuzzy CoCo by applying it to a hard, real-world proble-breast cancer diagnosis - obtaining the best results to date while expending less com- putational effort than formerly. 1 Introduction ...

Brought to you by PROSTATE CANCER FACTS What is prostate cancer ? Prostate cancer is a disease in which cancer cells develop in the prostate gland. The cancer cells divide without control or order and form a mass called a tumor. The prostate is about the size of a walnut. It sits just below the bladder in front of the rectum. How does my doctor know for sure I have prostate cancer ? Doctors use 2 tests to screen for prostate cancer — a PSA (prostate-specific antigen) blood test and a DRE (digital rectal exam). If either or both of these test results are not normal, the doctor may then perform a biopsy. Only a biopsy can confirm the presence of prostate cancer . |? PSA is a protein made by prostate cells. Elevated levels can suggest prostate cancer . |? Digital Rectal Exam During this exam, the doctor ...

attributedtotheincreasedincidenceofBarrett’s esophagus and its direct correlation with the development of esophageal adenocarcinoma. 4 Thisreviewdiscussesdiagnosis,treatment,and survivaloutcomesinpatientswithgastricadeno- carcinoma. Etiology Many risk factors have been associated with the development of gastric cancer , and the pathogenesisismostlikelymultifactorial (Table 1) . 2,5,6 Althoughsignificant,geneticabnormali- ties(suchasDNAaneuploidy,oncogeneampli- fication or mutation, and allelic loss of tumor suppressor genes) are not understood well enough to allow formulation of a sequence of progression to the development of gastric car- cinoma.Onepostulationonthedevelopmentof this disease involves a succession of histologic changesthatcommencewithatrophicgastritis, advancetomucosalmetaplasia,andeventually result in a malignancy. ...

Pancreatic Cancer : Diagnosis and Management ROBERT FREELOVE, M.D., Smoky Hill Family Medicine Residency Program, Salina, Kansas ANNE D. WALLING, M.B., Ch.B., University of Kansas School of Medicine-Wichita, Wichita, Kansas T he American Cancer Society esti- mated that 31,860 Americans would be diagnosed with pan- creatic cancer in 2004, and that 31,270 would die from the disease. 1 Pancre- atic cancer accounts for only 2 percent of all new cancers in the United States, but it is the fourth leading cause of cancer deaths. At the time of diagnosis , more than one half of pan- creatic cancers have metastasized, and only 8 percent are localized. The overall five-year survival rate is 4 percent. Localized cancers have a 17 percent survival rate. Survival rates have not improved during the past 25 years. 1 Pancreatic ...

Office of Technology Transfer Emory University Novel Construct for Gene Therapy and Cancer Diagnosis Inventors John A. Petros Dennis C. Liotta Applications Delivery nucleic acids to cells for gene therapy; diagnosis and treatment of metastatic cancers, especially prostate cancer Summary Prostate cancer is the most commonly diagnosed cancer in American males. No curative therapy exists for advanced or metastatic prostate cancer and chemotherapy is ineffective. Androgen ablation is palliative and non-curative. The molecular characterization of the disease has progressed rapidly in the past few years and it appears that in the future, gene therapy will be the treatment of choice for advanced and metastatic disease. Several potential genetic targets of therapy exist including replacement of tumor suppressor genes or metastasis suppressor genes, shutdown ...

1 FILE 93-2 Breast cancer is the most common cancer in women in North America, and the cancer most feared by women. This year, approximately 180,000 new cases of breast cancer will occur, and about 50,000 women will die from the disease. The incidence has risen in the past few decades. We have no known effective means of preventing this cancer (short of performing prophylactic mastectomy), so we must rely on the earliest possible diagnosis to have the best outcome. Breast cancer is one of the cancers where an early diagnosis can make a definite difference. Both prospective and retrospective studies have repeatedly shown a more favorable outcome with smaller primary lesions and fewer involved axillary lymph nodes. Of course, there are instances of biologically aggressive cancers that have an adverse prognosis no matter how small the primary tumor, but, in general, there is a direct correlation ...

Contents 2 Imaging Techniques Help Diagnose Previously Undetected Hepatic Tumors 2 New Physicians Join Liver Disease & Transplant Team 3 Liver Biopsy Offers Significant Insight for Managing Hepatitis C 4 Research Uncovers New Therapies for Treating Liver Cancer In cases of fibrolamellar hepatocellular carcinoma, AFP levels are notoriously normal. To increase the sensitivity of AFP to 85%, the des-gamma- carboxyprothrombin (DCP) tumor marker is used in some institutions, particularly in Japan. Periodic ultrasound examination offers the best HCC surveillance tool because it has more sensitivity and specificity than AFP. However, recommendations from recent conferences advocate: • Older patients with cirrhosis or with certain congenital metabolic conditions known to be at risk for ...

GYNAECOLOGICAL CANCER GUIDANCE : A PATIENT’S PATHWAY Patient Symptoms are often non-specific General Practitioner Assessment, examination, suspicion Management Plan: Primary treatment, adjuvant therapy & follow-up Cancer Unit Clinician & Multidisciplinary Team (MDT) Cancer Centre Clinicians & MDT Local Gynaecologist Assessment, investigation & Diagnosis or high index of suspicion Surgeon/Physician • Management plans to be agreed by the MDT at the Cancer Centre/ Cancer Unit and recorded in the patient’s notes • Treatment should only be conducted in the Cancer Centre or a Cancer Unit (ie Altnagelvin, Antrim, Craigavon and Ulster Hospitals) • Protocol- based investigations should be completed locally to expedite management • Each hospital should have arrangements, including rapid access facilities, ...

1 Research Proposal for MCEN4228/5228 Development of A Multiplex MRS Molecular Imaging Technique for Prostate Cancer Diagnosis Authors: David Tubert 1 , Keir Hart 1 , Victoria Remmel 2 , Andrew Knapp 1 and Hairong Zheng 1 Project Advisor: Professor Conrad Stoldt The department of Mechanical Engineering 1 The department of Integrative Physiology 2 University of Colorado at Boulder 4/30/2005 Page 2 2 I. Specific Aims Numerous molecular markers exhibit varying capacities in detecting prostate cancer and predict disease course. However, none of the current markers individually are able to provide precise diagnosis and discriminate accurately between indolent and aggressive cancers. Simultaneous detection of multiple ...

Press release 16 September, 2003 Rochdale doctor celebrates cancer diagnosis success A doctor at Rochdale Infirmary is celebrating his success in carrying out research into iron deficiency anaemia in a bid to diagnose gastrointestinal cancer early. Dr Achuth Shenoy’s unique research started just over two years ago, when he studied cases of anaemia due to iron deficiency. Anaemia is due to reduced levels of haemoglobin, a pigmented particle in the red blood cells, which carries oxygen through the lungs to the organs. The commonest cause of iron deficiency anaemia is chronic invisible blood loss, often due to a disease in the stomach or bowels, most important of which is cancer . Often, iron deficiency anaemia does not cause symptoms in early stages. However, when it is severe patients often appear pale, feel tired and are short of breath. Dr Shenoy says it’s well known that patients ...

Family Practice doi:10.1093/fampra/cmi093 Ó The Author (2005). Published by Oxford University Press. All rights reserved. Pathways to the diagnosis of colorectal cancer : an observational study in three UK cities Jacqueline Barrett a , Moyez Jiwa b , Peter Rose c and William Hamilton d Barrett J, Jiwa M, Rose P and Hamilton W. Pathways to the diagnosis of colorectal cancer : an observational study in three UK cities. Family Practice 2005; Pages 1–5 of 5. Background. Colorectal cancer can present in a variety of ways, and with any of several symptoms. Different referral routes from primary to secondary care cater for these different presentations. The route that has received most investment in the UK National Health Service is the 2-week clinic, but the proportions of patients taking this and other routes to diagnosis are largely ...

1 Mercantil and the Venezuelan Society Against Cancer united in fighting the disease MERCANTIL sponsors mobile unit for cancer diagnosis for low-income communities Fundacion Mercantil and the Venezuelan Society Against Cancer subscribed a Bs. 484 million agreement to create a trust devoted to fund the establishment and operation of a Mobile Unit for research and precocious diagnose of cancer for the benefit of low-income patients in Greater Caracas. This project has the support of the Ministry of Health and Social Development. The agreement was signed by Gustavo A. Marturet, President of MERCANTIL, and Fernando Guzman, President of the Venezuelan Society Against Cancer . During the blessing ceremony of the first unit, which will start operating for the San Bernardino community, both presidents expressed their satisfaction for the fruitful long-lasting relationship between their ...

a report by Paula M J Moonen and J Alfred Witjes PhD Student of Oncological Urology, and Professor of Oncological Urology, Department of Urology, Radboud University Nijmegen Medical Centre Bladder cancer presents in approximately 70% of patients as superficial (pTa, pT1, pTis) disease. Super- ficial bladder cancer is characterised by a high recurrence rate (50% to 80%) despite treatment. A minority of patients will show progression to muscle- invasive and often lethal disease. Frequent follow-up is consequently necessary and is performed with the current gold standard – cystoscopy with cytology. Both techniques are not perfect. Cystoscopy is invasive and does not provide complete detection of multifocal lesions. Moreover, carcinoma in situ (CIS), character- istically high-grade aggressive and unpredictable, is often under-diagnosed. Cytology has high ...

Table 1.28a - Spinal cord decompression procedures associated with any cancer diagnosis or inverterbrate disc disorders and spinal stensosis (except cervical) (ICD-9 140-209 inclusive + 722, 724.0, 724.3-724.5) in British Columbia 1999/2000 24 36 60 - - 16 35 - 60 61.5% 59.0% 60.0% - - 59.3% 67.3% - 60.0% 40.0% 60.0% 100.0% - - 26.7% 58.3% - 100.0% 15 25 40 5 - 11 17 - 40 38.5% 41.0% 40.0% 62.5% - 40.7% 32.7% - 40.0% 37.5% 62.5% 100.0% 12.5% - 27.5% 42.5% - 100.0% 39 61 100 8 6 27 52 7 100 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 39.0% 61.0% 100.0% 8.0% 6.0% ...

Cancer Diagnosis in Canada; Recommendations Canadian Strategy for Cancer Control: Diagnosis Working Group Final Report January 2002 Page 2 Diagnosis Working Group Report Canadian Strategy for Cancer Control 2 TABLE OF CONTENTS List of Abbreviations3 Executive Summary .4 Working Group Members .6 Framework.7 Relevant Topics..8 1. Methods of Diagnostic Assessment.8 2. Quality Assurance of Diagnostic Assessment.10 3. Staging Assessment13 4. Diagnostic Delay.14 5. Supportive Care17 6. Patient-Physician Communication.19 7. Education – Public/Patients ..20 7. Education – Family Physicians/Specialist Physicians 23 8. Diagnostic Assessment Units (DAUs) 24 Recommendations..26 Recommendation 1. Early presentation of signs/symptoms .26 Recommendation 2. Timely and accurate diagnostic ...

Table 1.27a - Scarification of the pleura associated with any cancer diagnosis (ICD-9 140-209 inclusive) in British Columbia 1999/2000 49 48 97 0 - 21 62 13 97 100.0% 100.0% 100.0% .0% - 100.0% 100.0% 100.0% 100.0% 50.5% 49.5% 100.0% .0% - 21.6% 63.9% 13.4% 100.0% 49 48 97 0 - 21 62 13 97 100.0% 100.0% 100.0% .0% - 100.0% 100.0% 100.0% 100.0% 50.5% 49.5% 100.0% .0% - 21.6% 63.9% 13.4% 100.0% n col % row % 46.5 Scarification of Pleura n col % row % Total Female Male Gender Total 0 - 19 20 - 39 40 - 59 60 - 79 80+ Age Total *** A dash (-) represents a procedure count of size 1 to 4, which has been suppressed, ...

CAD for Ultrasound - New Tool to Help Breast Cancer Diagnosis http://www.radiologytoday.net/archive/rt_091905p18.shtml 1 of 2 9/27/2005 2:46 PM For other artic September 19, 2005 CAD for Ultrasound — New Tool to Help Breast Cancer Diagnosis By Dan Harvey Radiology Today Vol. 6 No. 19 P. 18 Two Canadian medical companies plan to jointly market the first-ever computer-aided detection (CAD) system for breast ultrasound. The software solution, which will be marketed under the name Cedara B-CAD, was developed by the Medipattern Corporation of Toront distributed by the Cedara Software Corporation of Mississauga, Ontario. Both companies anticipate that this system will greatly impact th and treatment of breast cancer . Their optimism appears justified. It has already been demonstrated that B-CAD can boost radiologists’ dia confidence by helping them identify sonographic characteristics ...

PREOPERATIVE OVARIAN CANCER DIAGNOSIS USING NEURO-FUZZY APPROACH E.O. Madu, V. Stalbovskaya, B. Hamadicharef, E.C. Ifeachor S. Van Huffel, D. Timmerman Univ. of Plymouth, UK KU Leuven, Belgium ABSTRACT In this paper, we propose a neuro-fuzzy model for preoperative prediction of malignancy in ovarian tumours. The model is intended to form part of a reliable preoperative tool to discriminate between benign and malignant ovarian tumours to help clinicians decide the most appropriate form of treatment for patients. An aim of our work is to find a model that is understandable, practicable and capable of achieving accurate diagnosis . In this paper, we present our initial attempts to develop such a model using the Adaptive Network based Fuzzy Inference System (ANFIS). Our model predicts ovarian cancer malignancy using demographic, serum tumour marker and ultrasound- ...

The following educational document was prepared by staff of the Cancer Diagnosis Program of the National Cancer Institute. What Human Specimen Repositories Need to Tell Their IRBs: Points to Consider Introduction and Purpose: This document is an educational document intended to help individuals operating human specimen repositories provide the information their IRBs need to assess the protection of human subjects and compliance with federal human subjects regulations. It is intended to help repository developers/managers fully document repository operating procedures and policies. Effectively documenting procedures and policies should facilitate the IRB review and reduce the frustration of repository staff and IRB members. This document incorporates suggestions made by investigators, IRB members and federal program staff. Only fundamental items are listed. Additional information may be needed ...

Prostate Cancer : Causes, Diagnosis and Treatment Options PN 871083 Rev. B 10/05 Page 1 of 4 Prostate Cancer : Causes, Diagnosis and Treatment Options Causes of Prostate Cancer While the causes of prostate cancer are largely unknown, it is clear that the chance of developing prostate cancer increases in men over 50. Close relatives of men who have had prostate cancer are also more likely to be affected. Ethnic origin appears to play a part: Men of African heritage are at highest risk, and men of Far-Eastern descent have the lowest risk of developing prostate cancer . It may be possible to reduce the risk by following a low-fat diet and staying in shape. For example, men may reduce their risk through daily exercise and by cutting back on foods high in animal fat. Diagnosis Testing a blood sample for the level of Prostate Specific Antigen (PSA) plays an important part in the early ...

Gene extraction for cancer diagnosis by support vector machines–—An improvement Te Ming Huang, Vojislav Kecman * School of Engineering, The University of Auckland, 20 Symonds Street, Private Box 92019, Auckland, New Zealand Received 15 November 2004; received in revised form 4 January 2005; accepted 12 January 2005 Artificial Intelligence in Medicine (2005) 35 , 185—194 http://www.intl.elsevierhealth.com/journals/aiim KEYWORDS Cancer diagnosis ; Support vector machines; Gene selection; Feature selection Summary Objective: To improve the performance of gene extraction for cancer diagnosis by recursive feature elimination with support vector machines (RFE-SVMs): A cancer diagnosis by using the DNA microarray data faces many challenges the most serious one being the presence of thousands of genes and only several dozens ...

October 6, 2005 Breast Cancer : New Techniques for Diagnosis , Treatment, and Recovery Rache Simmons, M.D. & Amy Shapses, PT, CMDT November 10, 2005 Does Weight Matter? Jonathan Waitman, M.D. & Heather Bainbridge, R.D. February 16, 2006 Cardiac Risk Assessment: Cutting Edge Techniques Erica Jones, M.D. & James Min, M.D. March 16, 2006 Working Towards a Healthier You: Understanding Comprehensive & Preventative Care Shari Midoneck, M.D. & Mark Pochapin, M.D. April 20, 2006 To HRT or not To HRT; That is the Question Orli Etingin, M.D. & Margaret Polaneczky, M.D. May 11, 2006 The Body in Motion: Living with Arthritis and Osteoporosis Linda Russell, M.D. & Amy Shapses, PT, CMDT Time: Program: 6:15pm-7: 15pm Q & A following the seminar FREE ...

FAST TRACK Cancer survival is dependent on season of diagnosis and sunlight exposure Hyun-Sook Lim 1 * , Rahul Roychoudhuri 1 , Julian Peto 2,3 , Gary Schwartz 4 , Peter Baade 5 and Henrik Møller 1,2 1 King’s College London, Thames Cancer Registry, London, United Kingdom 2 Non-Communicable Disease Epidemiology Unit, Department of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, United Kingdom 3 Institute of Cancer Research, Sutton, United Kingdom 4 Department of Cancer Biology and Public Health Sciences, Wake Forest Comprehensive Cancer Center, Wake Forest University, Winston-Salem, NC 5 Viertel Centre for Research in Cancer Control, Queensland Cancer Fund, Spring Hill, Australia Sunlight is essential ...

Advances in the Diagnosis Advances in the Diagnosis and Treatment of Cancers and Treatment of Cancers Nigel A. J. McMillan Ph.D. Nigel A. J. McMillan Ph.D. Molecular Virology Molecular Virology Laboratory Laboratory Page 2 Two New Technologies Two New Technologies • Genetic disease profiling – DNA microarrays in Leukaemia • Gene Silencing Therapy – RNA interference for cervical cancers Page 3 RNA Interference RNA Interference The beginning The beginning Napoli C, Lemieux C, and Jorgensen R. (1990) Introduction of a chalcone synthase gene into Petunia results in reversible co-suppression of homologous genes in trans. Plant Cell 2 : 279-289 Parent Antisense Sense Page 4 ...

For more information, visit www.admetech.org ©2005 For the Advancement of Medical Technologies Overview of Current Prostate Cancer Diagnosis Methods: PSA Blood Tests Introduction The two diagnosis methods most often employed today are PSA blood testing and biopsies . PSA testing is the main diagnostic tool, and it has been shown to save lives. However, a recent National Cancer Institute study has shown that PSA testing, when abnormal, results in numerous false alarms and unnecessary biopsies, while a normal PSA does not rule out prostate cancer in about 15% of men. Without accurate imaging tools, prostate cancer care – diagnosis and treatment – is virtually blind. Indeed, the prostate is the last organ in a human body where biopsies are done blindly, without imaging-based visualization and guidance. Detection & Diagnosis : PSA Test u The most common ...

For more information, visit www.admetech.org ©2005 For the Advancement of Medical Technologies Overview of Current Prostate Cancer Diagnosis Methods: Blind Biopsy If a screening reveals an elevated PSA level, a patient may choose to have a blind biopsy performed to determine if prostate cancer is present. Blind Biopsy: u The prostate is the only organ in the human body where biopsy is done blindly. Imaging tools such as ultrasound is used to make sure biopsy is obtained from the entire prostate instead of a specific detected abnormality. u During a biopsy, the doctor first images your prostate, then inserts hollow biopsy needles into areas of the gland that may feel or look suspicious. A blind biopsy involves sampling at least 6 areas of the prostate with a needle to obtain a varied sample. 1 u If a tissue sample is taken because of an elevated ...

INFORMATION NOTE EUROPEAN GUIDELINES FOR QUALITY ASSURANCE OF BREAST CANCER SCREENING AND DIAGNOSIS , 4 th edition Background The European guidelines for quality assurance in breast cancer screening and diagnosis are based on over 20 years of experience in the EU Member States in implementation of regional and national breast cancer screening programmes based on mammography. They have been developed in the European Breast Cancer Network (EBCN) which was co-financed under the Europe against Cancer Programme. In the framework of the EBCN, scientists, programme administrators and other professionals from most of the EU Member States cooperate in exchanging experience on implementation and continuous improvement of breast screening programmes. In recent years, this cooperation has been extended to include quality assurance and best practice in diagnosis and treatment ...